Navigation Links
Drugs from the sea: New discoveries in marine biomedicine
Date:5/13/2011

Substances produced by living organisms found in natureso-called "natural products"have played a critical role in the development of drugs for life-threatening conditions. The anticancer agent Taxol was sourced from a plant, penicillin from a fungus, and a number of recent breakthroughs have resulted in the development and approval of anticancer drugs derived from marine sources such as coral and sponges.

To raise awareness about the vast potential of marine- and natural product-based biotechnology in the discovery and development of new drugs, the New York Academy of Sciences and the marine-based drug development company Zeltia S.A. are hosting a symposium, "New Frontiers in Marine Drug Discovery" at the New York Academy of Sciences Conference Center on May 20, 2011. This symposium will address the newly discovered and tremendous potential that the biodiversity of the marine ecosystem offers as a source for new therapeutically useful compounds, from the early stage drug discovery perspective of academia and the clinical therapy development perspective of industry.

The event will showcase recent technological improvements in natural product chemistry; review the landscape of marine-derived compoundsboth approved drugs and those in the development and trial stages; and explore examples of pioneering efforts, failures and successes in the translation of small molecules of natural marine origin into first-in-class and life-changing therapies for metastatic ovarian and metastatic breast cancer, among other diseases.

WHAT: A Scientific Symposium: New Frontiers in Marine Drug Discovery

WHO:

  • William Fenical, PhD, Director, Scripps Institution of Oceanography
  • Shirley Pomponi, PhD, President and CEO, Harbor Branch Oceanographic Institution
  • Juli M. Trtanj, Director, Oceans and Human Health Initiative, NOAA National Ocean Service
  • Roberto Weinmann, PhD, COO PharmaMar USA, a company of the Zeltia Group

WHEN: Friday May 20, 2011 | 8:00 AM - 7:00 PM

WHERE:
The New York Academy of Sciences
7 World Trade Center, 250 Greenwich St., 40th floor, New York, NY


'/>"/>

Contact: Marta Murcia
mmurcia@nyas.org
212-298-8641
New York Academy of Sciences
Source:Eurekalert

Related biology news :

1. Cholesterol-lowering drugs and the effect on muscle repair and regeneration
2. Vitamin C supplements may reduce benefit from wide range of anti-cancer drugs
3. Discovering drugs, biofuels in tropical seas
4. Academy participates in project to discover drugs, biofuels in tropical seas
5. European researchers harness unique properties of boron to develop new drugs and diagnostics
6. Self-assembling nano-fiber gel delivers high concentrations of clinically approved drugs
7. Moderate use averts failure of type 2 diabetes drugs in animal model
8. Montana State University researchers find gene that regulates molds resistance to drugs
9. MSU researcher studies ties between cholesterol drugs, muscle problems
10. New technique eliminates toxic drugs in islet transplant in diabetic mice
11. REGiMMUNE receives $12 million in grants to develop transplant and allergy drugs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/21/2016)... June 21, 2016 NuData Security announced today ... role of principal product architect and that ... of customer development. Both will report directly to ... The moves reflect NuData,s strategic growth in its ... high customer demand and customer focus values. ...
(Date:6/15/2016)... 15, 2016 Transparency Market ... Recognition Market by Application Market - Global Industry Analysis Size ... to the report, the  global gesture recognition market ... and is estimated to grow at a CAGR ... 2024.  Increasing application of gesture recognition ...
(Date:6/7/2016)... -- Syngrafii Inc. and San Antonio Credit Union (SACU) ... Syngrafii,s patented LongPen™ eSignature "Wet" solution into SACU,s ... in greater convenience for SACU members and operational ... document workflow and compliance requirements. Logo ... Highlights: ...
Breaking Biology News(10 mins):
(Date:12/2/2016)... Calif. , Dec. 2, 2016 Amgen (NASDAQ: ... AGN ) today announced the submission of a Marketing Authorization ... 215, a biosimilar candidate to Avastin ® (bevacizumab). The ... submitted to the EMA. "The submission of ... Amgen seeks to expand our oncology portfolio," said Sean ...
(Date:12/2/2016)... ... December 01, 2016 , ... ACEA Biosciences, Inc. announced ... I/II clinical trials for AC0010 at the World Conference on Lung Cancer 2016, taking ... update on the phase I/II clinical trials for AC0010 in patients with advanced non-small ...
(Date:12/2/2016)... (PRWEB) , ... December 01, 2016 , ... ... Computational Science Symposium (CSS) and the popularity of US Single Day Events (SDE) ... place in early Summer 2018, in Raleigh, NC. Topics of the pharmaceutical and ...
(Date:12/2/2016)... ... December 01, 2016 , ... Orthogonal, a ... their recent FDA Class II 510(k) clearance for their flagship medical device, SimplECG. ... remote cardiac monitoring devices that rely on cloth-based nanosensors. While other companies have ...
Breaking Biology Technology: